QScreen AI Finalizes Tiered Screening System, Boosts US Institutional Pipeline with Advanced Escalation Review

Tiered Screening Architecture Enhances Operational Efficiency While Ensuring Fairness and Due Process

The release details a two-stage screening approach designed to meet operational demands at institutional sites. The initial stage acts as a rapid readiness gate, completing assessments in approximately 90 seconds using QScreen’s patented single-camera technology on standard laptops or tablets equipped with webcams. Results are classified as clear or ambiguous, with clear outcomes requiring no further action.

The escalation tier, distinguishing QScreen’s platform from competitors, routes ambiguous results to a second-stage extended evaluation. This stage assesses physiological markers such as smooth-pursuit eye tracking, response inhibition, and sustained attention. Offered once per session under site-configured policies, this tier serves as a structured review rather than a retest or appeal. While second-stage results provide additional context, they cannot overturn first-stage findings. Certain critical safety signals bypass escalation and are immediately directed to human personnel.

Human Oversight Maintained Throughout the Assessment Process

A core principle emphasized is that the software flags concerns and collects evidence, but trained supervisors or licensed professionals retain ultimate decision-making authority. No employee is removed from duty solely based on algorithmic output. The platform records every assessment step and final human decision in session logs, accessible via the supervisor console with supporting documentation.

Dr. Rahul Kushwah, COO of QScreen AI, explained that the tiered architecture addresses the challenge of assessing entire workforces at shift changes, which is impractical at scale. The 90-second gate combined with extended assessments for ambiguous cases enables workforce-wide screening within normal shift-start periods. The escalation tier offers a "deeper and fairer look" before any supervisor engagement, applying a uniform, fully documented process.

Platform Runs on Existing Hardware Without Installation Needs

QScreen’s commercial strategy emphasizes minimal technical barriers at deployment sites. The browser-based platform requires no installation and operates on existing hardware like laptops or tablets with webcams, leveraging the company’s patented single-camera method. This approach reduces capital costs and simplifies integration for customers.

The company developed this solution with operational realities in mind, acknowledging workforce resistance to camera systems that could send employees home. Transparency, fairness, and human decision preservation are positioned as key competitive advantages in the institutional screening market.

Fourth Consecutive Monthly Development Milestone Achieved

The tiered screening architecture completion represents the fourth major development milestone announced in as many months: full platform integration in April, passive voice analysis in May, US Patent No. 12,640,164 granted last week, and the current architecture finalization.

This steady cadence of milestones reflects a structured development approach, enhancing functionality and securing intellectual property. Investors may view this consistent progress as indicative of the company’s execution capability and timeline toward commercial launch.

US Institutional Pipeline Growth Driven by Global Frontier Advisors Collaboration

Partnership with Global Frontier Advisors has yielded a focused pipeline of potential institutional and industrial evaluators in the southeastern US. Dr. Kushwah plans to conduct in-person demonstrations in the region soon as part of the company’s US channel strategy.

Alongside US prospects, QScreen is engaging provincial correctional health authorities in Canada, targeting both US institutional settings and Canadian correctional or health facilities. Securing a first signed evaluation agreement remains a key near-term objective.

Site Licensing Model Based on Workforce Coverage Over Per-Test Fees

QScreen’s commercial model departs from typical per-test billing, instead offering site licenses based on workforce coverage. This aligns with the tiered architecture’s goal of comprehensive workforce screening within standard operational windows rather than selective or repeated testing.

This coverage-based licensing appeals to institutional clients seeking predictable costs linked to workforce size rather than variable fees tied to testing frequency. The model is integrated into discussions with US partners and forms a core part of the company’s value proposition.

Patent Protection Secures Single-Camera Screening Innovation

The recently granted US Patent No. 12,640,164 safeguards QScreen’s single-camera screening technology, forming a foundational competitive asset. The tiered architecture and platform implementation are built upon this patented method.

This intellectual property protection is significant for investors assessing competitive barriers and market sustainability. The company links the patent grant directly to ongoing commercial demonstrations, highlighting its importance in sales efforts.

Platform Validation and Usage Defined by Regulatory and Company Guidelines

The announcement includes disclaimers noting that platform validation used simulated scenarios and synthetic patient data, with live performance potentially differing from lab results. The platform functions as a clinical decision support tool requiring confirmation by licensed healthcare professionals before any action.

QScreen screening tools are designed solely for risk assessment and decision support, not as diagnostic medical devices, and do not replace professional medical judgment. These qualifications align with regulatory frameworks governing healthcare decision-support technologies.

Development Momentum Indicates Near-Term Commercialisation Readiness

The company’s emphasis on four successive monthly milestones, patent protection, active institutional pipeline, and scheduled in-person demos suggests it is nearing commercial readiness. Achieving a signed evaluation agreement is a stated near-term goal, signaling progression from demonstration to formal customer testing.

Investors will likely monitor QScreen’s ability to secure evaluation agreements and convert demonstrations into customer commitments, which could impact market perceptions of the company’s commercial execution and revenue potential.